LARIMAR THERAPEUTICS INC
NASDAQ: LRMR (Larimar Therapeutics, Inc.)
Kemas kini terakhir: semalam, 9:42PM3.97
-0.03 (-0.75%)
| Penutupan Terdahulu | 4.00 |
| Buka | 4.02 |
| Jumlah Dagangan | 1,491,985 |
| Purata Dagangan (3B) | 4,353,649 |
| Modal Pasaran | 412,415,264 |
| Harga / Buku (P/B) | 5.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 May 2026 |
| EPS Cair (TTM) | -1.51 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.37% |
| Nisbah Semasa (MRQ) | 7.48 |
| Aliran Tunai Operasi (OCF TTM) | -86.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -52.86 M |
| Pulangan Atas Aset (ROA TTM) | -31.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Larimar Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.43% |
| % Dimiliki oleh Institusi | 103.11% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Dafna Capital Management Llc | 31 Dec 2025 | 939,164 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 14.00 (Citigroup, 252.65%) | Beli |
| Median | 13.00 (227.46%) | |
| Rendah | 12.00 (Wedbush, 202.27%) | Beli |
| Purata | 13.00 (227.46%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 5.73 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 03 Mar 2026 | 12.00 (202.27%) | Beli | 5.51 |
| 25 Feb 2026 | 11.00 (177.08%) | Beli | 5.95 | |
| Citigroup | 25 Feb 2026 | 14.00 (252.64%) | Beli | 5.95 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |